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INTRODUCTION
 
Current evidence shows that medications are 
underused in the treatment of alcohol use 
disorder, including alcohol abuse and 
dependence.* 
* Within this document “alcohol abuse” and “alcohol
dependence” are used when discussing medication indications 
or research that is based upon this terminology. For a summary
of important differences between DSM-IV and DSM-5, please 
see the box on this page. 
This is of concern because of the 
high prevalence of alcohol problems in the 
general population.1,2 For example, data show 
that an estimated 10 percent to 20 percent of 
patients seen in primary care or hospital 
settings have a diagnosable alcohol use 
disorder.3,4 People who engage in risky drinking 
often have physical and social problems related 
to their alcohol use. Problems with alcohol 
influence the incidence, course, and treatment 
of many other medical and psychiatric 
conditions.2 
Yet, of the 18.0 million people who met the 
criteria for alcohol dependence or abuse in 
2013, only a small subset (1.4 million) received 
any type of formal treatment (excluding mutual-
help groups)—ranging from a single meeting 
with a counselor to participation in a specialized 
treatment program.3 
Although many experts in addiction believe that 
patients with moderate or severe alcohol-
related problems should be offered medication-
assisted treatment (MAT) on a routine basis,1 
considerable resistance to the use of MAT 
persists. A diagnosis of alcohol use disorder 
continues to carry significant social exclusion, 
which affects both the individual who receives 
the diagnosis and the health care professionals 
to whom that individual may turn for care. In 
part, the social exclusion continues because of 
a lack of understanding of alcohol use disorder 
as a treatable medical disorder2 even though, 
more than 50 years ago, the American Medical 
Association (AMA) affirmed that dependence on
alcohol and other drugs is a medical disorder.5 
The AMA encouraged physicians and other 
clinicians, health care organizations, and 
policymakers to frame all their activities and 
decisions in ways that reflect that fact. 
To clarify the situation, the National Institute on 
Alcohol Abuse and Alcoholism (NIAAA) and the 
Substance Abuse and Mental Health Services 
Administration (SAMHSA) jointly convened a 
Consensus Panel on New and Emerging 
Pharmacotherapies for Alcohol Use Disorders 
and Related Comorbidities (see Appendix A). 
The panel, which brought together experts in 
alcohol research, clinical care, medical 
education, and public policy, reviewed current 
evidence on the effectiveness of available 
medications for the treatment of alcohol use 
disorders and developed guidance for the use 
of medications in clinical practice.1 The panel’s 
guidance is summarized in this document. 
Alcohol Use Disorder: A Comparison 
Between DSM-IV and DSM-5 
“In May 2013, the American Psychiatric 
Association issued the 5th edition of the 
Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5). Although there is
considerable overlap between DSM-5 and 
DSM-IV, the prior edition, there are several 
important differences: DSM–IV described two 
distinct disorders, alcohol abuse and alcohol 
dependence, with specific criteria for each. 
DSM-5 integrates the two DSM-IV disorders, 
alcohol abuse and alcohol dependence, into a 
single disorder called alcohol use disorder 
(AUD) with mild, moderate, and severe 
subclassifications. Under DSM-5, anyone 
meeting any two of the 11 criteria during the 
same 12-month period would receive a 
diagnosis of AUD. The severity of an AUD— 
mild, moderate, or severe—is based on the 
number of criteria met:
 Mild: The presence of 2 to 3 symptoms
 Moderate: The presence of 4 to 5 
symptoms
 Severe: The presence of 6 or more 
symptoms
The DSM-5 eliminates legal problems as a 
criterion, adds craving as a criterion for an AUD 
diagnosis and modifies some of the criteria 
descriptions with updated language.” 
––National Institute on Alcohol
Abuse and Alcoholism6 
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CONSIDERING MEDICATIONS 

Direct involvement of physicians and other health
care professionals in identifying and treating 
alcohol use disorder is possible, practical, and 
necessary. The medications described here have 
been shown to be effective in, and are approved 
by the Food and Drug Administration (FDA) for, 
the management of alcohol dependence or the 
prevention of relapse to alcohol use.7,8,9,10,11 
Specifically: 
 	 Acamprosate calcium is indicated for the 
maintenance of abstinence from alcohol in 
patients dependent on alcohol who are 
abstinent at treatment initiation.
 	 Disulfiram is an aid in the management of 
selected patients who want to remain in a 
state of enforced sobriety so that supportive 
and psychotherapeutic treatment may be 
applied to best advantage.  
 	 Oral naltrexone (naltrexone hydrochloride 
tablet) is indicated for the treatment of alcohol 
dependence.
 	 Extended-release injectable naltrexone is 
indicated for the treatment of alcohol 
dependence in patients who have been able 
to abstain from alcohol in an outpatient 
setting.
Clinicians should consider prescribing one of 
these medications when treating a patient who is 
dependent on alcohol or who has stopped 
drinking but is experiencing problems including 
cravings or relapses. Patients with moderate or 
severe alcohol use disorder, including those who 
have physiologic dependence or who are 
experiencing cravings and have not improved in 
response to psychosocial approaches alone, are 
particularly strong candidates for medication-
assisted treatment.1,2 
Medications should be prescribed as part of a 
comprehensive treatment approach that includes 
counseling and other psychosocial therapies 
(through referral to a psychiatrist, psychologist, or
professional counselor) and social supports 
(through participation in Alcoholics Anonymous 
and other mutual-help programs).1,2 
Table 1 summarizes information about each 
medication approved by the FDA for the 
treatment of alcohol use disorder and/or the 
prevention of relapse to alcohol use.
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TABLE 1: Medications Approved for Use in the Treatment of Alcohol Use Disorder† 
† This table highlights some properties of each medication. It does not provide complete information and is not intended as a substitute for the package inserts or other drug reference sources 
used by clinicians (see http://www.dailymed.nlm.nih.gov for current package inserts). For patient information about these and other drugs, visit the National Library of Medicine’s MedlinePlus 
(http://www.medlineplus.gov). Whether a medication should be prescribed and in what amount are matters to be discussed between an individual and his or her health care provider. The
prescribing information provided here is not a substitute for the clinician’s judgment, and the National Institutes of Health and SAMHSA accept no liability or responsibility for use of the 
information in the care of individual patients. 
Disulfiram Naltrexoneoral and extended release injectable
formulations
Acamprosate 
delayed-release tablets 
Frequency of
Administration 
Daily Daily (oral) or monthly (extended-release 
injectable)
Three times per day 
Principal Action When taken in combination with alcohol, 
causes a significant physical reaction, 
involving nausea/vomiting, flushing, and 
heart palpitations. The knowledge that such
reactions are likely if alcohol is consumed
acts as a deterrent to drinking. 
Given sufficient amounts of alcohol in the 
patient’s system, more severe reactions 
may occur, such as respiratory depression, 
cardiovascular collapse, arrhythmias, 
myocardial infarction, acute congestive
heart failure, unconsciousness, 
convulsions, and death.  
Blocks opiate receptors that are involved in the 
rewarding effects of drinking and craving for
alcohol.  
Extended-release injectable naltrexone is 
administered every 4 weeks, thereby minimizing 
opportunities for nonadherence, as compared with 
daily oral ingestion. The monthly injection also
produces a more consistent and predictable blood 
level of the drug, because the depot injection
bypasses first-pass metabolism. 
Is thought to reduce symptoms of protracted 
abstinence by counteracting the imbalance 
between the glutamatergic and GABAergic 
systems associated with chronic alcohol 
exposure and alcohol withdrawal.
Clinical 
Uses/Ideal 
Candidates
Candidates include patients dependent on
alcohol who have completed alcohol 
withdrawal. Ideally, candidates are 
committed to abstinence and willing to take 
disulfiram under the supervision of a family
member or treatment program. 
Oral naltrexone and extended-release injectable 
naltrexone are indicated for the treatment of 
alcohol dependence in patients who can abstain 
from alcohol in an outpatient setting before the 
initiation of treatment. Naltrexone has not been 
shown to be effective in patients who are drinking 
at treatment initiation.
Both formulations may have the greatest benefit in 
patients who can discontinue drinking on their own 
for several days before treatment initiation. 
Extended-release injectable naltrexone is also 
indicated for the prevention of relapse to opioid 
dependence following detoxification.
Acamprosate is indicated for the 
maintenance of abstinence in patients who 
are dependent on alcohol and are abstinent 
at treatment initiation. 
The efficacy of acamprosate in promoting 
abstinence has not been demonstrated in
subjects who have not completed 
detoxification or who have not achieved 
alcohol abstinence before beginning 
treatment. 
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Disulfiram Naltrexoneoral and extended release injectable
formulations
Acamprosate 
delayed-release tablets 
Contraindications Contraindicated in the presence of severe 
myocardial disease or coronary occlusion, 
psychoses, pregnancy, and in those with 
high levels of impulsivity, suicidality, and 
hypersensitivity to disulfiram or to other 
thiuram derivatives used in pesticides and
rubber vulcanization.
Patients who are taking or have recently
taken metronidazole, paraldehyde, alcohol, 
or alcohol-containing preparations (e.g., 
cough syrups, tonics) should not be given 
disulfiram. 
Disulfiram labeling also includes several 
important precautions regarding drug–drug 
interactions. See the package insert for 
specific contraindications. 
Contraindicated in patients receiving opioid
analgesics and those receiving long-term opioid 
therapy or anticipating a need for opioids (e.g., 
surgery), because it could precipitate a severe
opioid withdrawal or block opioid analgesia; 
patients currently dependent on opioids, including 
those being maintained on opioid agonists such as 
methadone or partial agonists such as 
buprenorphine; patients in acute opioid withdrawal; 
patients who have failed the naloxone challenge 
test or whose urine tests positive for opioids.  
Contraindicated in patients with a history of
sensitivity to polylactide-co-glycolide, 
carboxymethyl cellulose, or any components of the 
diluent used for the injectable medication.
It should not be given to patients whose body mass 
precludes intramuscular (IM) injection with the 2­
inch needle provided. Inadvertent subcutaneous 
injection may cause a severe injection-site 
reaction. 
Although not in current labeling, the consensus of 
the panel is that use should be avoided in patients 
with serum aminotransferase levels greater than 
five times the upper limit of normal, except where 
the benefits outweigh the risks. 
Contraindicated in patients with severe
renal impairment and in those who have a 
known hypersensitivity to the drug or its 
components.
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Disulfiram Naltrexoneoral and extended release injectable
formulations
Acamprosate 
delayed-release tablets 
Warnings Use with caution in patients with heart 
disease, diabetes, hypothyroidism, 
epilepsy, cerebral damage, chronic or 
acute nephritis, acute hepatitis or other 
hepatic diseases, and in patients older than
60.
Hepatic toxicity (including hepatic failure 
resulting in liver transplantation or death) 
has been infrequently reported. Severe and 
sometimes fatal hepatitis associated with
disulfiram may develop after many months 
of therapy. Hepatic toxicity has occurred in 
patients with or without a history of 
abnormal liver function.
Patients should be advised to immediately 
notify their physician of any early
symptoms of hepatitis, including fatigue, 
weakness, malaise, anorexia, nausea, 
vomiting, jaundice, or dark urine.
Liver function tests (taken at baseline and 
10–14 days later) are suggested to detect 
any hepatic dysfunction that may result 
from disulfiram therapy. In addition, 
complete blood counts and serum 
chemistries, including liver function tests, 
should be monitored.
Psychotic reactions have been noted, 
attributable to the unmasking of underlying 
psychoses in patients.
Cases of hepatitis and clinically significant liver 
dysfunction were observed in association with
extended-release injectable naltrexone treatment. 
Discontinue use of naltrexone in the event of 
symptoms or signs of acute hepatitis.
Use with caution in patients with moderate to 
severe renal impairment. 
Patients should take no opioids, including opioid-
containing medications, for a minimum of 7 days 
before starting naltrexone to avoid precipitating 
opioid withdrawal. 
Patients needing opioid analgesia or patients with 
a history of opioid use disorder may respond to 
lower doses of opioids after treatment with 
extended-release injectable naltrexone. Failure to 
carefully titrate opioid dose could result in 
potentially life-threatening opioid intoxication and 
overdose.  
Patients should be told of the serious 
consequences of trying to overcome the opioid 
blockade.
Before initiating treatment with
acamprosate, evaluate the patient’s renal 
function through a standard panel for urea, 
electrolytes, and serum creatinine to rule 
out severe renal impairment. 
For patients with moderate renal 
impairment (creatinine clearance of 30–50 
mL/min), a reduced dose of acamprosate 
(one 333 mg tablet 3 times a day) is 
recommended. 
Because of elevated risk of diminished
renal function in people ages 65 or older, 
baseline and frequent renal function tests 
are important in this population. 
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Disulfiram Naltrexoneoral and extended release injectable
formulations
Acamprosate 
delayed-release tablets 
Use in Pregnant 
and Postpartum 
Women
Pregnancy: The FDA has not assigned a 
pregnancy category. The safe use of this 
drug in pregnancy has not been 
established. Therefore, disulfiram should 
be used during pregnancy only when, in 
the judgment of the physician, the probable 
benefits outweigh the possible risks.
Nursing: Do not give disulfiram to nursing 
mothers. 
Pregnancy: FDA Pregnancy Category C‡ 
Nursing: Transfer of naltrexone and 6ß-naltrexol 
into human milk has been reported with oral 
naltrexone. Because animal studies have shown 
that naltrexone has a potential for tumorigenicity
and other serious adverse reactions in nursing 
infants, an individualized treatment decision should 
be made whether a nursing mother will need to 
discontinue breastfeeding or discontinue 
naltrexone.
Pregnancy: FDA Pregnancy Category C‡ 
Nursing: It is not known whether 
acamprosate is excreted in human milk.
SOURCE: SAMHSA and NIAAA. (2012, September). Report of the SAMHSA-NIAAA Consensus Panel on New and Emerging Pharmacotherapies for Alcohol Use 
Disorders and Related Comorbidities. Rockville, MD: SAMHSA. 
‡ Animal studies have shown an adverse effect on the fetus and there are no adequate, well-controlled studies in humans, but potential benefits may warrant use of the drug in some pregnant 
women despite potential risks. 
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SCREENING AND ASSESSING PATIENTS 
Clinicians should routinely screen their patients for 
at-risk drinking, provide brief interventions as 
needed, and assess for alcohol use disorder when 
indicated.2
Screening for Risky Alcohol Use  
Universal screening for alcohol problems can be 
conducted concurrently with screening for other 
medical disorders as part of a routine examination. 
By systematically screening every patient with a 
validated screening tool, the clinician can effectively 
identify patients with risky or dependent levels of 
alcohol use. This approach has been shown to be 
superior to a case-finding approach. 
Screening also should be conducted before 
prescribing one of the many medications that may 
interact negatively with alcohol or if a patient reports 
using an over-the-counter product or herbal 
preparation that may precipitate an adverse reaction. 
Screening is especially important in patients who: 
• Are pregnant or trying to conceive. 
• Are at risk for binge drinking or heavy drinking. 
• Have health problems that may be induced or 
exacerbated by alcohol (e.g., cardiac arrhythmia, 
depression or anxiety, dyspepsia, insomnia, liver 
disease, a history of traumatic injury). 
• Have one or more chronic health problems (e.g., 
diabetes, heart disease, hypertension, 
gastrointestinal [GI] disorders, chronic pain) that 
are not responding to treatment.7
• Have social or legal problems that may be 
caused or worsened by alcohol use (e.g., 
marital/family issues, driving-while-under-the-
influence convictions). 
Screening can be conducted through use of a 
simple, validated self-report instrument such as the 
Alcohol Use Disorders Identification Test (AUDIT) 
(http://www.whqlibdoc.who.int/hq/2001 
/WHO_MSD_MSB_01.6a.pdf), which takes fewer 
than 5 minutes to complete, or a single interview 
question: “How many times in the past year have 
you had ___ or more drinks in a day?” (five drinks 
for men and four drinks for women). The single 
question can be used at any time, either in 
conjunction with AUDIT or alone.7 Study results 
have shown that, when used in a primary care 
setting, the single question was 82 percent sensitive 
in detecting individuals who had alcohol problems.12 
A useful overview of screening and intervention 
strategies can be found in a document called 
Alcohol Misuse: Screening and Behavioral 
Counseling Interventions in Primary Care 
(http://www.uspreventiveservicestaskforce 
.org/uspstf/uspsdrin.htm) (see Appendix B). Many 
U.S. primary care physicians rely on these United 
States Preventive Services Task Force 
recommendations to guide how they conduct 
preventive practice. Clinicians should also consider 
using Screening, Brief Intervention, and Referral to 
Treatment (SBIRT), an approach in which screening 
is followed up as appropriate with brief intervention, 
and with referral to treatment for those needing 
more extensive care (http://www.samhsa.gov/sbirt) 
(see Appendix B). 
Assessing the Need for Medication-
Assisted Treatment 
A patient who reports one or more heavy drinking 
days in the past year (or who has an AUDIT score 
greater than 8) should receive further 
assessment.2,7,8,9,10,11 Consideration should be 
given to the factors motivating a patient toward 
treatment, the patient’s stage of change, the 
potential for relapse, the severity of any 
concomitant medical and psychiatric problems, the 
patient’s ability to tolerate medications, and 
whether the patient is pregnant (in which case, 
medications associated with adverse physical 
effects, such as disulfiram, should be avoided). 
Patient History. Although the evidence 
supporting inclusion of each element is not 
conclusive, consensus opinion is that an 
assessment should include a medical and 
psychiatric history, a substance use history, and an 
evaluation of family and psychosocial supports.13
Information from family members and significant 
others can provide useful perspectives on the 
patient’s status, as can communication with or 
records from clinicians who treated the patient in 
the past.13
It also is advisable to access the patient’s 
prescription drug use history through the state’s 
prescription drug monitoring program (PDMP), 
where available,13 to detect unreported use of 
other medications, such as opioid analgesics or 
sedative-hypnotics, that may interact negatively 
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with alcohol or with alcohol treatment 
medications. 
Physical Examination. The physical 
examination should evaluate neurocognitive 
function, identify sequelae of alcohol use, and 
look for evidence of hepatic dysfunction.14 
Although many patients with alcohol use disorder
have no specific abnormal findings on physical 
examination, when present, these abnormal 
findings provide evidence of the severity of a 
patient’s alcohol problem. For example, 
longstanding alcohol consumption may be 
marked by many classic features, such as 
physical manifestations of cirrhosis, 
encephalopathy, and vitamin deficiencies. 
Alcohol consumption may also provoke 
tachycardia (including supraventricular 
tachycardias), tremor of the hand or tongue, 
elevated blood pressure, hepatosplenomegaly, a
tender liver edge, peripheral neuropathy, spider 
angiomata, conjunctival injection, and 
unexplained trauma.2,14,15,16 
Laboratory tests help confirm the presence of 
heavy drinking and identify alcohol-related 
damage. 
Laboratory Testing. Laboratory tests help 
confirm the presence of heavy drinking and 
identify alcohol-related damage. Initial and follow-
up laboratory testing can help motivate patients 
and reinforce their progress in treatment.2 
Although no single laboratory test can definitively 
point to an alcohol use disorder diagnosis in the 
absence of other information,14 the following tests 
can be helpful in identifying heavy drinking and 
possible alcohol-related abnormalities:16,17 
 	 Blood alcohol levels are useful measures of 
recent alcohol consumption and can indicate 
physical or legal incapacity to perform specific 
tasks, including driving. 
 	 Carbohydrate-deficient transferrin (CDT), 
gamma-glutamyl transpeptidase (GGT), and 
aspartate aminotransferase (AST) levels can 
be useful biomarkers because they often are 
elevated in people who have chronically 
consumed significant amounts of alcohol.16 
Some studies suggest that biomarkers such 
as AST, GGT, and CDT are most useful when 
used in combination.16,17,18,19 
 	 Tests for ethyl glucuronide (EtG), an alcohol 
metabolite, are highly sensitive for alcohol; 
however, this sensitivity is a potential 
drawback as well as a strength, because 
exposure to even small amounts of alcohol 
(e.g., those found in some foods and 
cosmetics) can trigger a positive test 
result.16,17,20 However, use of appropriate 
laboratory cutoffs make it more likely that a 
positive test is an indication of recent alcohol 
use.20
	  Phosphatidylethanol, another alcohol 
metabolite, is a promising new biomarker that 
is highly sensitive in detecting chronic drinking 
(three or more drinks a day for 1 or 2 weeks). 
It can be detected in the blood for 2 to 4 
weeks after drinking has stopped.16,20,21,22 
Several laboratory tests can help the clinician 
establish a patient’s overall health status and 
identify alcohol-related damage and 
contraindications to the use of specific 
medications.23,24 These include: 
	  Complete blood count: Alcohol overuse can 
cause anemia and have direct toxic effects on 
bone marrow. An assessment of hematologic 
laboratory indices is useful when considering 
pharmacologic treatment of alcohol use 
disorder. Many people who are alcohol 
dependent have elevated corpuscular volume 
(macrocytosis).
	  Testing for vitamin deficiencies: Individuals 
with alcohol use disorder may not consume a 
healthful diet, resulting in vitamin deficiencies 
that lead to abnormal cellular function. For 
example, deficiencies in thiamine, folic acid, 
and pyridoxine are seen in people with
physiological alcohol dependence, and those 
deficiencies contribute to abnormal cell 
function. Vitamin deficiencies may also lead to 
Wernicke-Korsakoff/amnesic syndrome in 
patients whose alcohol consumption is very 
excessive. 
	  Hepatic and renal testing: The use of
medications to treat alcohol use disorder 
requires evaluation of organ systems that are 
involved in the metabolism and excretion of 
those medications. For example, naltrexone 
and disulfiram should be used with caution in 
patients who have liver disease, whereas 
naltrexone and acamprosate should be used 
with caution in patients with renal impairment. 
Therefore, hepatic and renal system testing 
8 
  
 
 
 
 
 
 
 
 
 
 
 
Medication for the Treatment of Alcohol Use Disorder: A Brief Guide 
should be done as part of the patient
 
assessment. 

 	 Other tests: Initial laboratory work should 
include a urine toxicology screen to assess for 
other substances, and women of childbearing 
age should have a pregnancy test. 
DEVELOPING A TREATMENT PLAN AND 

SELECTING A MEDICATION 

If a patient’s initial assessment supports a 
diagnosis of moderate or severe alcohol use 
disorder, the next step is to develop a 
comprehensive treatment plan.24 
Setting Goals for Medication-
Assisted Treatment 
The provider and patient should mutually agree 
on an initial goal and be willing to refine and 
revise that goal as treatment progresses.2 For 
example, in working with a patient who is 
unwilling to set a goal of complete abstinence, 
the clinician should support the patient in 
reducing his or her drinking as an interim goal, 
while maintaining that complete abstinence is the
safer strategy, with a greater chance of long-term 
7success.
Certain conditions warrant complete abstinence 
from alcohol rather than a reduction in use. 
These involve individuals who are or may 
become pregnant, are taking a medication that 
may cause a harmful drug interaction, or have a 
medical or psychiatric disorder that is associated
with or exacerbated by alcohol use.7,24 
If a patient engages in risky drinking but does not
meet the criteria for an alcohol use disorder, the 
clinician should use his or her professional 
judgment in helping the patient decide whether 
reducing or abstaining from alcohol is the more 
appropriate goal, based on factors such as a 
family history of alcohol problems and the 
patient’s age or history of traumatic injuries 
related to drinking.24 
It may be helpful to provide the patient with a 
copy of National Institute on Alcohol Use and 
Alcoholism’s booklet Rethinking Drinking or to 
refer the patient to the associated Web site (see 
Appendix B). 
Components of the Treatment Plan 
Steps to achieve the patient’s goal should be 
outlined in a treatment plan, which should be 
developed in consultation with the patient and 
address the following points:13 
 	 The medication and other therapies to be 
employed, with a rationale for their use 
 	 Schedules for follow-up office visits and 
laboratory testing to monitor the patient’s 
progress and health status 
 Reasons for participation in mutual-help 
groups 
 Involvement of family or significant others in 
treatment 
 	 A plan for treating co-occurring medical or 
psychiatric conditions and other substance 
use disorders, including smoking 
 	 Criteria for discontinuing the use of medication 
or other therapies and referring the patient for 
a higher level of care, if indicated
Whenever a medication is to be used, the 
treatment plan should include steps that will 
promote medication adherence. Depending on 
the needs of the patient, these might include 
specific strategies for remembering to take 
medications, use of blister card packs or pill 
boxes, a schedule for monitoring medication 
adherence that reflects the patient’s history of 
adherence to other medication regimens, and 
steps to involve the patient’s family members in 
monitoring adherence.2,7 
Educating the Patient and 
Obtaining Informed Consent 
Before treatment begins, the patient should 
understand what to expect, including how the 
proposed medication works and the associated 
risks and benefits. This is best achieved through 
face-to-face discussions and the use of written 
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educational materials (see Appendix B for 
sources of helpful information). 
Elements of effective patient education include 
the following points:2,13 
 	 Information about alcohol use disorder as a 
chronic medical disorder
 A description of what to expect from treatment 
 Information about the medication and the 
reasons it was selected, including a 
discussion of potential risks and benefits and 
the time to full effect
 	 For women of childbearing age, explanation of 
the importance of using an effective birth 
control method 
 	 Clear information about what to do if the 
patient resumes alcohol use after a period of 
abstinence
 	 The importance of informing all physicians 
and dentists that the patient is taking a 
medication for alcohol use disorder, to avoid 
inadvertent drug interactions, especially when 
surgery (including dental surgery) is being 
considered
 	 Symptoms that should be reported to the 
prescribing physician
 	 A discussion of the importance of concurrent 
psychosocial treatment and participation in a 
mutual-help group 
 	 Plans for follow-up care 
The patient should be advised to carry a medical 
alert card identifying the medication-assisted
treatment, describing potential adverse effects 
(e.g., symptoms of a disulfiram–alcohol reaction), 
and providing contact information for the treating 
physician or institution in an emergency.13 
The fact that a patient has received and 
understands this information should be 
documented in the patient record. Clinicians also
are advised to obtain a written informed consent 
from the patient before initiating treatment.13 
Evaluating the Need for Medically 
Managed Detoxification 
Alcohol withdrawal syndrome can be severe and 
potentially fatal, so it is particularly important to 
assess the need for medically managed 
withdrawal.25 Patients who need medically 
supervised detoxification may need to be referred 
to an addiction specialist or addiction treatment 
program that can provide medically monitored 
withdrawal treatment. 
Withdrawal generally begins within 24 to 48 
hours after the blood alcohol level drops and can
persist for 5 to 7 days. Symptoms include 
restlessness, irritability, anxiety, and agitation; 
anorexia, nausea, and vomiting; tremor; elevated
heart rate; increased blood pressure; insomnia,
intense dreaming, and nightmares; poor 
concentration and impaired memory and 
judgment; increased sensitivity to sound, light, 
and tactile sensations; auditory, visual, or tactile 
hallucinations; delusions (usually of a paranoid or
persecutory nature); grand mal seizures; 
hyperthermia; delirium with disorientation 
concerning time, place, person, and situation; 
and fluctuations in level of consciousness.25 
In assessing the likelihood and potential severity 
of withdrawal, the most useful clinical factors are 
the patient’s previous withdrawal experience and 
the number of previous withdrawals (treated or 
untreated), with three or four withdrawal episodes 
indicating an increased likelihood that severe 
withdrawal symptoms will occur unless adequate
medical care is provided.26 
Use of a standardized clinical rating instrument 
for withdrawal, such as the Clinical Institute 
Withdrawal Assessment for Alcohol Scale, 
Revised (CIWA-Ar) (https://umem.org/files 
/uploads/1104212257_CIWA-Ar.pdf), is helpful
because it guides the clinician through multiple 
domains of alcohol withdrawal and allows for 
semi-quantitative assessment of nausea, tremor, 
autonomic hyperactivity, anxiety, agitation, 
perceptual disturbances, headache, and 
disorientation.26,27 In multiple studies, the CIWA-
Ar has been found to have high reliability and 
validity, and it takes only 2 to 5 minutes to 
complete.26 
Some benzodiazepines are effective in treating 
the symptoms of alcohol withdrawal. For 
example, diazepam carries a labeled indication
for relief of acute agitation, tremor, impending or 
acute delirium tremens, and hallucinosis in acute
alcohol withdrawal. Chlordiazepoxide also is 
frequently used for the management of alcohol 
withdrawal symptoms.
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Integrating Pharmacologic and 
Nonpharmacologic Therapies 
Some patients may respond to psychosocial 
interventions and others to medication therapy 
alone, but most patients benefit from a 
combination of these approaches. The various 
approaches—medications for moderate or 
severe alcohol use disorder, professional 
counseling, and mutual-help groups—are 
complementary; they address different aspects of
alcohol use disorder: neurobiological, 
psychological, and social. Offering the full range
of effective treatments increases patient choice 
and the potential for a positive outcome, as no 
single approach is universally successful.7 
Psychosocial Treatments. Psychosocial 
treatments can enhance adherence to the 
treatment plan, including use of prescribed 
medications, and thus improve treatment 
outcomes. Conversely, to the extent that they 
reduce craving and help patients maintain 
abstinence, medications may help patients be 
more receptive to psychosocial interventions.2,28 
Almost all studies of medications for the 
treatment of alcohol use disorder have included 
some type of counseling, and it is recommended
that all patients for whom these medications are 
prescribed receive at least brief counseling. 
Evidence is accumulating that weekly or biweekly 
brief (i.e., 15–20 minutes) counseling sessions 
combined with use of a medication is an effective 
treatment for many patients in early recovery.2,7,9 
This counseling typically focuses on encouraging
abstinence, adherence to the medication 
regimen, and participation in mutual-help 
7groups.
Although psychiatrists may be able to deliver 
psychosocial therapies onsite, most clinicians 
need to refer patients for individual or group 
therapy.2 
Encouraging Participation in Mutual-Help 
Programs. The support of a mutual-help group 
can be helpful to long-term recovery. The oldest, 
best known, and most accessible mutual-help 
program is offered by Alcoholics Anonymous 
(AA). Patients may resist attending AA meetings
and may fear that disclosure of medication use 
will make them unwelcome.2 Although some AA 
members have negative attitudes toward 
medication, the organization itself supports 
appropriate medication use.29 Providers should 
encourage patients to try different group 
meetings until they find one that is a good fit. 
Lists of local meetings to give to patients can be 
obtained from http://www.aa.org. 
Other mutual-help groups, although not as 
universally available as AA, have a strong 
presence in many communities. Contact 
information for several groups that may be 
helpful to patients and their families is provided in
Appendix B.
Addressing Co-Occurring Disorders 
Research studies show that the most effective 
way to treat co-occurring disorders is through 
integrated treatment,30,31,32 which is defined as 
any mechanism by which treatment interventions 
for multiple co-occurring disorders are delivered 
within the context of a primary treatment 
relationship or service setting. The term 
co-occurring acknowledges the need for a unified 
treatment approach to meet the substance use,
mental health, and related needs of a patient 
and, thus, is the preferred model of treatment.2 
Integrated treatment assumes that each disorder
is primary and in need of simultaneous care.
It is not always possible to provide truly 
integrated care in primary care settings, although 
standardized psychosocial treatments have been 
developed that are more readily provided in 
general practice settings.1,31 When providers 
cannot provide a full range of onsite care, they 
need to identify resources in their practice 
community and develop relationships with those 
providers to streamline and coordinate care as 
much as possible. This includes developing and 
maintaining resources for psychosocial 
services.1,7 In addition, the patient may need 
assistance with obtaining a referral, securing an 
initial appointment within a reasonable time 
frame, and addressing issues with health 
insurance coverage. 
When medication management and addiction 
treatment services are delivered by separate 
providers, close coordination and integration of 
services is essential. All individuals involved in 
the patient’s treatment, including addiction 
medicine specialists, need to establish close
linkages and open communications.31,32 
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Treating Adolescents and Young 
Adults 
Empirical validation of the value of medication-
assisted treatment in adolescents is lacking. 
Moreover, none of the available medications is 
approved by the FDA for use in people younger 
than age 18. Therefore, younger adolescents in 
need of treatment should be referred to a 
clinician or program specializing in adolescent 
addiction.1,33 
However, in older adolescents and young adults,
the limitations of available psychosocial 
interventions for youth and the demonstrated 
effectiveness of pharmacologic interventions in 
adults suggest that it may be reasonable to 
consider pharmacologic treatments for patients in 
this age group.34,35 
There are no specific safety contraindications for
older adolescents/young adults for the 
medications discussed here, and available 
information supports the safe and judicious use 
of medications in this population.36 This is 
particularly true of older adolescents and young 
adults who have severe alcohol use disorder, as 
well as those who have not achieved success 
with psychosocial interventions alone and those 
who exhibit more adult patterns of moderate and 
severe alcohol use disorder.37 
Treating Pregnant and Postpartum 
Women 
Pregnancy and postpartum care present 
opportunities to screen and intervene for alcohol 
use disorder, which is clearly associated with 
fetal abnormalities and long-term cognitive 
problems in offspring. In fact, research has not 
identified any safe level of drinking during 
pregnancy.38 Use of alcohol during pregnancy 
may result in miscarriage, stillbirth, or premature 
delivery. Complications seen in the infant may 
include fetal alcohol syndrome or fetal alcohol 
spectrum disorder. 
Unfortunately, none of the medications used to 
treat alcohol use disorder have been shown in 
clinical trials to be absolutely safe for pregnant or 
nursing women. Therefore, these medications 
should be used during pregnancy only when, in 
the judgment of the physician, the probable 
benefits outweigh the possible risks.39 Pregnant 
or nursing patients should be referred to an 
addiction specialist or a specialist in managing 
high-risk pregnancies for care.40 
Treating Older Adults 
Alcohol and other substance use are significant 
problems among older adults, in whom alcohol 
use disorder is associated with many health and 
social problems that increase the risk of 
hospitalization, nursing home placement, and 
death.41,42,43 A study projected that the number of 
adults ages 50 and older with a substance use 
disorder will double from 2.8 million (the annual 
average in the period from 2002 through 2006) to 
5.7 million in 2020.44 
Accurately diagnosing an alcohol use disorder in
an older adult can be done more effectively when
clinicians are cognizant of the following 
challenges faced by this population group:45 
 	 Shame: Older adults are more likely to hide 
their substance-related problems because 
they are more likely to feel shame and less 
likely to seek help or talk about it.
 	 Problem ignored or minimized by family:
Family members may feel ashamed, be in 
denial, ignore the problem, believe the 
problem is not serious, or feel that their older 
relatives have a right to drink or use drugs. 
 	 Misdiagnosis: Health care practitioners often 
mistake alcohol or drug problems for 
symptoms of other conditions that are 
common among older adults, such as 
depression or dementia. 
Pharmacotherapies for alcohol use disorder 
appear to be as effective and safe for older 
adults as for younger adults. However, because 
older adults are more likely than their younger 
counterparts to have comorbid medical problems 
and thus to be using multiple medications and 
have decreased ability to eliminate medications, 
care must be taken to avoid adverse drug 
events.45 
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As a result, the following factors need to be 
considered when prescribing pharmacotherapy to 
older adults:45,46 
 Dose reductions and frequent renal function 
tests may be necessary when prescribing 
acamprosate to individuals in whom 
decreased renal function (creatinine clearance 
rate <70 mL/min/1.73 m2) is evident.
 In patients ages 61 and older, disulfiram 
doses may need to be reduced. Disulfiram 
interacts with multiple drugs, so caution 
should be exercised in prescribing it to older 
adults at risk for polypharmacy.
Selecting a Medication 
The FDA has approved three oral medications 
(disulfiram, acamprosate, and naltrexone) and 
one injectable medication (extended-release 
injectable naltrexone) for the treatment of alcohol 
dependence or the prevention of relapse to 
alcohol use.7,24 In addition to factors specific to 
each medication, the clinician should consider 
the patient’s past experience with particular 
medication-assisted treatment medications; 
beliefs and opinions about which 
pharmacotherapy may be most helpful; level of 
motivation for abstinence; medical status and 
contraindications for each medication; and 
history of medication adherence.2 
Although further research with large patient 
samples is required before definitive advice can 
be offered on which medication to select for a 
particular patient, information for matching 
patients to particular pharmacotherapies is 
summarized below.24,40,47,48,49 Medications are 
listed in the approximate order in which the FDA 
approved them for the treatment of alcohol 
dependence.
Disulfiram. Approved by the FDA as an alcohol 
abuse deterrent in 1951, disulfiram disrupts the 
metabolism of alcohol, resulting in an unpleasant 
reaction, which can be severe whenever an 
individual taking disulfiram consumes
alcohol.50,51,52,53,54 
Mechanism of Action. The disulfiram reaction  
is caused by a blockade of aldehyde 
dehydrogenase, which causes an accumulation 
of acetaldehyde when alcohol is ingested. When 
this occurs, the physical reaction can include 
nausea, flushing, and heart palpitations.40 Unlike 
other medications approved to treat alcohol use 
disorder, disulfiram does not directly affect 
opiate, gaba-aminobutyric acid, or glutamate 
receptors in the brain. Disulfiram blocks 
dopamine-beta-hydroxylase in the brain, thereby 
increasing dopamine levels and reducing 
noradrenaline levels.51 
Formulation. Disulfiram is manufactured as a 
white to off-white odorless and almost tasteless 
powder. It is supplied in 250 mg and 500 mg 
tablets for oral administration.50 
Dosing and Administration. The initial and 
average maintenance dose is 250 mg per day 
(doses range from 125 mg to a maximum dose of 
500 mg per day). The disulfiram tablet is taken by
mouth once a day; it may be crushed and mixed
with water, coffee, tea, milk, soft drink, or fruit 
juice.50 Faulty bioactivation in some patients can
yield too low a concentration of the active 
metabolite needed to inhibit aldehyde
dehydrogenase, and the 500 mg dose may be 
more effective in these patients.52 Patients who 
experience mild side effects (as described later in 
this section) may obtain relief by reducing the 
dose to 125 mg daily.51 
Efficacy. The effectiveness of disulfiram in the 
prevention and limitation of relapse to alcohol 
use is supported by multiple studies.47,48 It should 
be noted that disulfiram was approved prior to 
the requirement that drugs be shown to be 
effective before being marketed was enacted. An
evidence report from the Agency for Healthcare 
Research and Quality concluded that four 
placebo-controlled randomized clinical trials of
oral disulfiram produced mixed results.49 
Although disulfiram was shown to reduce the 
frequency of drinking days in two trials, in neither
study did it improve relapse rates compared with
placebo. Two studies that examined patient 
adherence with oral disulfiram found it to be 
low,53,54 and a third study had a 46 percent 
dropout rate.55 
Investigators who argue that disulfiram is 
effective in preventing relapse to alcohol use 
frequently emphasize the importance of the 
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circumstances in which it is administered. In 
particular, the level and quality of supervision a 
patient receives while taking disulfiram are 
believed to be important components of its 
success.55,56 Some studies have found that court-
ordered disulfiram therapy promotes efficacy by 
increasing adherence to the disulfiram regimen.57 
Use of incentives, patient contracts, the 
cooperation of a significant other in fostering 
adherence, the use of regular reminders to the 
patient, and patient behavioral counseling and 
social support may enhance disulfiram efficacy 
by improving adherence. Overall, methodologic 
limitations and mixed results make it difficult to 
state with certainty what percentage of patients 
benefit from disulfiram.1 However, disulfiram is a
medication that should be considered for patients 
with no contraindications and who might have 
major consequences should they use alcohol. 
Safety. The severity of a disulfiram–alcohol 
interaction is proportional to the dose of 
disulfiram and the amount of alcohol consumed. 
A reaction lasts 30 to 60 minutes in mild cases. 
In more severe cases, the reaction can continue
for several hours or until the alcohol is 
metabolized. When effects are severe, palliative
and supportive measures may be needed to 
restore blood pressure and treat shock.50 
Other safety issues include both minor side 
effects and more serious adverse reactions. 
Minor side effects, which typically occur during 
the first 2 weeks of therapy, include
skin/acneiform eruptions, headache, allergic 
dermatitis, impotence, mild drowsiness, fatigue,
and metallic or garlic-like aftertaste.2,50 
Serious adverse reactions, although rare,51 
include the following conditions:2,50 
 Optic neuritis: Usually diagnosed after a 
patient complains of visual disturbances, 
optic neuritis is addressed by discontinuing 
disulfiram and conducting (or referring the 
patient for) an ophthalmologic examination.
 Peripheral neuritis, polyneuritis, peripheral 
neuropathy: Usually diagnosed after a patient 
complains of paresthesias (numbness or 
tingling), these conditions require that
disulfiram be discontinued. A neurological 
evaluation should be conducted.
 Hepatitis, including cholestatic and fulminant 
hepatitis, as well as hepatic failure: When 
symptoms of hepatic dysfunction are reported 
or observed, liver function tests should be 
obtained. When clinical or laboratory 
evidence of hepatic dysfunction is found, 
disulfiram should be discontinued 
immediately and liver function and other 
symptoms monitored closely. 
Drug Interactions. There is evidence that 
disulfiram interacts with a number of drugs, 
including benzodiazepines, isoniazid, rifadin 
(Rifampin®), metronidazole, oral anticoagulants 
such as warfarin, oral hypoglycemics, phenytoin, 
and theophylline. The potential severity of some 
drug interactions makes it essential that patients 
be cautioned to report all medications they are 
taking and not to start any new medication 
without checking with the disulfiram 
prescriber.14,53 
Clinical Recommendations. Patients who are 
good candidates for treatment with disulfiram 
include those who are motivated for treatment 
and want to achieve abstinence, who are 
medically appropriate, who can receive 
supervised dosing, and who understand the 
consequences of drinking alcohol while taking
disulfiram. It may be an appropriate short-term 
therapy for a patient in recovery who anticipates
being in a situation that may trigger craving for 
alcohol (e.g., a family holiday visit) and who 
requests an additional incentive to remain 
abstinent.2,53,54,55,56,57 
Naltrexone. Naltrexone hydrochloride is a long-
acting opioid antagonist. The FDA approved oral 
naltrexone for the treatment of alcohol 
dependence or alcoholism in 1994. The low rate 
of retention and adherence encountered with oral 
naltrexone led to the development of the 
extended-release injectable formulation, which 
the FDA approved for the treatment of alcohol 
use disorder in 2006.2,24 
Mechanism of Action. Naltrexone has affinity 
for the mu, kappa, and delta opiate receptors. 
The actual neurobiological mechanisms by which
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naltrexone induces the reduction in alcohol 
consumption observed in alcohol-dependent 
patients is not entirely understood. Preclinical
data suggest the involvement of the endogenous 
opioid system.58 
As an antagonist at the mu receptor, naltrexone 
may reduce the urge to consume alcohol through
two mechanisms: 
1. 	 Suppression of alcohol-mediated beta­
endorphin stimulation of dopamine neurons in 
the nucleus accumbens 
2. 	 Reduction of beta-endorphin disinhibition of 
the tonic inhibition of dopamine cells by 
gamma-aminobutyric acid neurons in the 
ventral tegmental area47,59,60 
Extended-release injectable naltrexone is 
metabolized in the liver to the opioid antagonist 
6ß-naltrexol.61 Two peak blood levels occur after 
injection: a transient initial peak occurs 
approximately 2 hours after injection and a 
second peak occurs approximately 2 days later. 
About 14 days after injection, the blood level 
slowly begins to decline in a linear fashion. The 
absorption of extended-release naltrexone is 
mediated by its gradual and prolonged release 
for 2 to 4 weeks after injection through hydrolysis 
of copolymer microspheres.7,24 
Formulation. Oral naltrexone is marketed in 50 
mg tablets.7,24 
Extended-release injectable naltrexone was 
developed by embedding the drug molecule 
within microspheres composed of a 
biodegradable copolymer, resulting in release 
of the active ingredient over a period of 
approximately 4 weeks.62,63 It is packaged in a kit 
containing a vial of naltrexone as a dry powder, 
which must be suspended in a liquid diluent 
immediately before use. Each kit contains a 
syringe and five needles: one for mixing the 
microspheres with the diluent and four needles 
(two 1.5-inch needles and two 2-inch needles) for 
injecting the suspension into the upper outer 
quadrant of the gluteal muscle.63 
Kits must be refrigerated during storage but 
should be brought to room temperature 
approximately 45 minutes before an injection is 
given. The suspended microspheres in solution
must be mixed vigorously to prevent clumping, 
which can clog the needle during injection.63 
Dosing and Administration. The oral 
naltrexone tablet is taken by mouth once a day. 
The dose recommended for most patients is 50 
mg per day, given in a single dose.2,7 GI side 
effects are common and dose dependent, so 
patients with GI side effects should have a trial of 
therapy at a lower dose.
The approved dose of extended-release 
naltrexone is 380 mg, given approximately once 
a month. Clinical trial data confirm earlier studies
indicating that there is no need to adjust the dose 
for the patient’s body weight.63 
Extended-release injectable naltrexone is 
administered by intramuscular (IM) gluteal 
injection. It is retained at the site of injection so 
that its active compound is released consistently 
over approximately 4 weeks,63 and measurable 
levels may be observed for longer than 1 month. 
Efficacy. Oral naltrexone has been shown to 
reduce relapse to heavy drinking, which is 
defined as three or more drinks per day for 
women and four or more for men.59,60,64 In a 
systematic review of 11 double-blind, placebo-
controlled trials, researchers found that oral 
naltrexone, when combined with psychosocial 
treatments, reduced relapse rates at 3 months in 
patients with alcohol dependence.59 (Almost all 
studies were done in patients who were abstinent 
at baseline.) Short-term outcomes in favor of 
naltrexone included fewer patients relapsing to 
alcohol dependence (38% with naltrexone versus
60% with placebo), fewer patients returning to 
drinking (61% versus 69%), reduced craving for 
alcohol, and fewer drinking days. Thus, it is 
especially useful in patients who have a history of 
drinking relapses.65 
Extended-release injectable naltrexone is 
approved for use only in patients who can refrain
from drinking for several days before treatment 
begins—a subgroup of the patient population in 
whom efficacy has been demonstrated. For 
example, in a 6-month, randomized, double-
blind, placebo-controlled trial involving 624 
individuals, patients who received a 380 mg dose 
of extended-release injectable naltrexone had a 
25 percent reduction in heavy drinking days 
compared with those receiving placebo. The 
effect was greater in males.66 A secondary
analysis found that patients who had 4 or more 
days of abstinence before beginning treatment 
with extended-release injectable naltrexone 
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experienced particularly good treatment 
outcomes.67 
Safety. Naltrexone generally is well tolerated, 
although it has the potential to precipitate severe 
opioid withdrawal in patients who are opioid 
dependent.2 Common side effects include 
nausea, vomiting, headaches, dizziness, 
fatigue, anxiety, and somnolence, with 
nausea and vomiting the most frequently 
reported.59,60,64,65,66,67,68 Less common side effects 
include diarrhea, constipation, chest pains, 
joint/muscle pain, rash, insomnia, excessive
thirst, loss of appetite, perspiration, mild 
depression, increased tears, and delayed 
ejaculation.2,24 
More serious adverse reactions, with suggestions 
for management, include the following:59,60 
 	 Precipitated opioid withdrawal: To mitigate 
withdrawal symptoms, discontinue 
naltrexone, provide supportive treatments 
(i.e., hydration and antispasmodic and 
antidiarrheal medications) until the symptoms 
resolve, and provide a ß2-agonist such as 
clonidine. Watch for clonidine side effects, 
including dizziness, hypotension, fatigue, and 
headache.
 	 Hepatic toxicity: Discontinue naltrexone. 
 	 Naltrexone overdose: Treat the patient 
symptomatically under close supervision. 
Contact a poison control center for current 
information. 
A side effect unique to extended-release 
injectable naltrexone is injection-site reaction, 
which involves pain or tenderness at the injection
site, usually resolving in 2 to 5 days. Swelling, 
erythema, bruising, and pruritus may occur, 
generally as the result of an inadvertent 
subcutaneous injection. Serious reactions include 
induration, cellulitis, hematoma, abscess, sterile 
abscess, and necrosis. Rarely, these reactions 
require surgical intervention, such as
debridement of necrotic tissue, which can result 
in significant scarring. To prevent problems, 
providers should be trained in proper techniques 
for IM injections.63 
Drug Interactions. Potential drug interactions 
involve cough and cold preparations, 
antidiarrheal medications, thioridazine, 
yohimbine, and nonsteroidal anti-inflammatory 
drugs (which can elevate liver enzymes). 
As noted earlier, naltrexone blocks the effects of
opioid analgesics.13 For more information, see 
the discussion of Special Considerations in Pain 
Management on page 18.13,14,68,69 
Clinical Recommendations: Oral Naltrexone.
Oral naltrexone is most effective when prescribed
for patients who are highly motivated and/or 
supported with observed daily dosing and who 
are abstinent at the time treatment is initiated.70,71 
Naltrexone also appears to be effective in the 
following patient populations: 
 	 Patients who have a history of opioid use 
disorder and who are seeking treatment for an 
alcohol use disorder. Naltrexone reduces the 
reinforcing effects of and curbs cravings for 
both opioids and alcohol. 
 	 Patients with intense craving for alcohol 
during treatment. These individual may 
experience greater medication benefit than 
patients with low levels of craving for 
alcohol.72 
 	 Patients who have a family history of alcohol 
use disorder. Both laboratory studies and 
clinical trials suggest that patients with a 
family history of alcohol problems may benefit 
more from treatment with naltrexone than 
patients who do not have such a history.73 
Clinical Recommendations: Extended-
Release Injectable Naltrexone. Extended-
release injectable naltrexone benefits people 
appropriate for treatment with oral naltrexone, as 
well as the following:1,68,69,74 
 	 Patients who are abstinent at initiation of 
treatment. Extended-release injectable 
naltrexone has not been shown to be effective 
in patients who are drinking at the time 
treatment is initiated.
 	 Patients who are seeking treatment for 
moderate or severe alcohol use disorder while 
in recovery from co-occurring opioid use 
disorder. The FDA approved extended-
release injectable naltrexone in 2010 for the 
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prevention of relapse to opioid dependence, 
following opioid detoxification.
Acamprosate. Acamprosate is a delayed-
release synthetic compound that is indicated for 
maintaining abstinence in patients who are 
alcohol dependent and are abstinent at the time 
treatment is initiated.75 The FDA approved the 
medication for the treatment of alcohol use 
disorder in 2004.7 
Mechanisms of Action. Although the precise 
mechanisms of action of acamprosate are not yet 
known, they appear to involve beneficial 
modulation of the glutamatergic neurotransmitter 
system (including antagonism of the mGlu5 
metabotropic glutamate receptor) to counteract 
the imbalance between the glutamatergic and 
GABAergic systems associated with chronic 
alcohol exposure and alcohol withdrawal.75 
Formulation. Acamprosate is supplied as 
enteric-coated 333 mg tablets.7 
Dosing and Administration. Two 333 mg 
delayed-release tablets are taken by mouth three 
times a day, with or without food (a lower dose 
may be effective with some patients and must be 
used with those with impaired renal function). 
Pills must be swallowed whole, not crushed or 
broken.7,76 
Efficacy. Acamprosate has been shown to be an 
effective treatment for dependence on alcohol, 
with no abuse potential and no significant 
interaction with medications commonly used to 
treat substance use and mental disorders.76 
Acamprosate’s efficacy is primarily due to its 
ability to reduce the negative symptoms 
associated with the period immediately following 
alcohol withdrawal.77 
Safety. Acamprosate has a good safety profile: 
no development of tolerance has been reported, 
there appears to be no risk of overdose, and 
there is no clinically significant interaction 
between acamprosate and other medications. 
The most common side effect is diarrhea, which 
usually is mild and transient, typically 
disappearing within the first few weeks of 
treatment.78 Less common side effects include
intestinal cramps and flatulence, headache, 
increased or decreased libido, insomnia, anxiety, 
muscle weakness, and dizziness.
Rare but serious side effects include suicidal
ideation and suicide attempts. In such patients, 
acamprosate should be discontinued and the 
patient monitored for worsening of depression.76 
A psychiatric consultation should be obtained 
and/or an antidepressant medication prescribed
as needed.
Drug Interactions. There are no known drug 
interactions with acamprosate.14,24 
Clinical Recommendations. Research on 
patient characteristics has not definitively 
identified particular characteristics that would 
predict which patients would benefit most from 
acamprosate.77 However, evidence suggests that 
acamprosate may be most effective for the 
following types of patients:59,79 
 	 Patients who are abstinent from alcohol at the 
time treatment is initiated and who are 
motivated to maintain abstinence. A study 
found that these patients had better outcomes 
with acamprosate than did patients who 
wanted only to reduce their drinking.78 
 	 Patients with hepatic disease or those who 
are being treated with opioids for pain or 
addiction. Acamprosate is eliminated renally 
and does not affect endogenous or 
exogenous opioids.
 	 Patients who are coping with multiple medical 
issues and who are taking many other 
medications. There are no clinically significant 
drug interactions with acamprosate, so it can 
be a safe medication for many patients taking 
other medications.
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MEDICATION-ASSISTED TREATMENT 

A patient who is being considered for medication-
assisted treatment must be free of the 
contraindications listed in Table 1, including 
severe medical or psychiatric problems that 
would make the individual a poor candidate for 
treatment with a medication.1,2 
The following steps are recommended for 
initiating treatment with any of the medications 
approved for the management of moderate or 
severe alcohol use disorder or the prevention of 
relapse to alcohol use:1,2,7 
 	 Educate the patient about medication-assisted
treatment and the specific medication being 
recommended. 
 	 Obtain informed consent for medication-
assisted treatment. 
 	 Complete a medical, psychiatric, and
substance use history, including history of 
cardiovascular disease, diabetes, thyroid 
disease, seizure disorder, central nervous 
system impairment, and kidney or liver 
disease.
 	 Determine which prescription and over-the­
counter medications the patient is taking, 
including herbal preparations.
 	 Perform a physical examination, baseline liver 
and kidney function tests, urine toxicology 
screen, and (in women) a pregnancy test.
 	 Assess the patient for allergies to the 
proposed medication and to other 
medications. 
 	 For women, assess reproductive status, 
including current pregnancy or plans to 
become pregnant or to breastfeed.
Initiating Treatment with 
Disulfiram 
Steps in initiating treatment with disulfiram are as 
follows:2,55,56 
 	 Wait until the patient has abstained from 
alcohol for at least 12 hours and/or until the 
breath or blood alcohol level is zero.
 	 Perform an electrocardiogram if clinically 
indicated (e.g., in a patient with a history of 
heart disease). 
 	 Confirm the absence of allergy to disulfiram. 
 	 Perform the following tests to confirm
abstinence and determine baselines after 
stabilization:
a. 	 Breath or blood alcohol tests, if clinically 
indicated to confirm abstinence
b. 	 Liver function tests: alanine 
aminotransferase, aspartate 
aminotransferase, gamma glutamyl­
transferase, alkaline phosphatase, 
lactate dehydrogenase, bilirubin, total 
protein, albumin, prothrombin time
c. 	 Complete blood count and routine 
chemistries, if clinically indicated 
d. 	 Kidney function tests: routine blood urea 
nitrogen, creatinine
Initiating Treatment with 
Naltrexone 
Naltrexone has not been shown to be effective in 
patients who are drinking at treatment initiation.
The clinician should consider how best to induct
a prospective patient into treatment with 
extended-release injectable naltrexone. 
Advise all patients being treated for alcohol use
disorder that it is imperative to notify health care 
providers of any recent use of opioids or any 
history of opioid use disorder before starting 
extended-release injectable naltrexone, to avoid 
precipitation of opioid withdrawal. A urine drug 
screen should be conducted to verify abstinence 
before beginning induction.80 If patients are to be 
treated for both alcohol and opioid substance 
use disorder, they should be off all opioids, 
including prescription opioid analgesics, for a 
minimum of 7 to 10 days before starting 
naltrexone.81 Patients transitioning from opioid 
agonist therapy to extended-release injectable 
naltrexone may be vulnerable to precipitation of
withdrawal symptoms for as long as 2 weeks. 
Ensure that patients understand that withdrawal 
precipitated by administration of an opioid 
antagonist is different from the experience of 
spontaneous withdrawal that occurs with 
discontinuation of opioids in a dependent 
individual. Withdrawal precipitated by an opioid 
antagonist may be severe enough to require 
hospitalization. 
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When discontinuing naltrexone for patients with a 
history of co-occurring opioid use disorder, 
advice on opioid overdose prevention should be 
provided. After a period of abstinence from 
opioids, tolerance is greatly reduced. This means 
a previously tolerated amount of opioid could 
result in opioid overdose. Patients discontinuing 
opioid antagonist therapy in order to receive pain 
management with opioid analgesics should also 
be advised of this risk. Consider providing 
patients at risk of opioid overdose with a 
prescription for naloxone. SAMHSA’s Opioid 
Overdose Toolkit includes strategies for 
developing such a plan to address emergency 
reversal of actual or suspected opioid 
overdose.82 
Pretreatment with oral naltrexone is not required
before induction onto extended-release injectable
naltrexone.63,68 
Dosing and Administration. For appropriate
candidates, the recommended dose of extended-
release injectable naltrexone is 380 mg, 
delivered intramuscularly approximately every 30 
days, alternating buttocks for each subsequent 
injection. The following cautions should be 
observed:24,63,68 
 	 Injectable naltrexone should be administered 
only by a medical professional (a physician, 
nurse, physician assistant or nurse 
practitioner) who knows how to administer IM 
gluteal injections.
 	 Injectable naltrexone is packaged in a kit 
containing a vial of naltrexone as a dry 
powder that must be reconstituted with a liquid 
diluent immediately before use. Kits must be 
refrigerated during storage but should be 
brought to room temperature approximately 
45 minutes before an injection is given. The 
reconstituted microspheres in solution must 
be mixed vigorously to prevent clumping, 
which can clog the needle during injection.
 	 A syringe and five needles are provided: one 
for mixing the microspheres with the diluent 
and four needles (two 1.5-inch needles and 
two 2-inch needles) for injecting the 
suspension into the upper outer quadrant of 
the gluteal muscle. Body habitus should be 
assessed before each injection for each 
patient to ensure that needle length is 
adequate for IM administration. Injectable 
naltrexone must be administered only with 
one of the administration needles supplied in 
the carton. A spare administration needle of 
each size is provided in case of clogging. 
 	 Proper IM injection technique is essential. 
Serious injection-site reactions, sometimes 
requiring extensive surgical debridement, 
have been observed with extended-release 
injectable naltrexone. It has been reported 
that these severe reactions may be more 
common if the product is inadvertently 
administered subcutaneously rather than 
intramuscularly. 
 	 The medication should be administered every 
4 weeks. If a dose is delayed or missed, the 
next injection should be administered as soon 
as possible. However, it is not recommended 
that the medication be readministered at less 
than 4-week intervals. 
 	 It is not recommended that the medication be 
administered at a dose higher than 380 mg. 
Clinicians are advised to download prescribing 
information on extended-release naltrexone at 
http://dailymed.nlm.nih.gov/dailymed/index.cfm. 
Special Considerations in Pain 
Management. As discussed earlier, both oral 
and extended-release naltrexone block the 
effects of opioid analgesics. However, pain 
management for patients using extended-release 
injectable naltrexone can be even more 
complicated than for those taking oral naltrexone, 
because of the long-acting nature of the 
injectable formulation. In an emergency, regional 
analgesia, conscious sedation, use of non-opioid 
analgesics, or general anesthesia may be 
needed for pain management.2,63 
If regional anesthesia is not used, then a larger 
amount of the opioid analgesic may be needed to 
override the opioid blockade. This may result in 
respiratory depression that is deeper and more 
prolonged than usual. For this reason, a rapid-
onset, short-acting opioid analgesic that 
minimizes the duration of respiratory depression 
is preferred. The amount administered should be
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titrated to the needs of the patient, who should be 
monitored closely by trained medical 
personnel.1,2 
Initiating Treatment with 
Acamprosate 
Acamprosate typically is initiated 5 days after the 
cessation of alcohol use. The drug typically 
reaches full effectiveness in 5 to 8 days.2,75,76 
Acamprosate therapy should be continued even 
if a patient relapses to alcohol use.1 
Treating People with Co-Occurring 
Disorders 
Co-Occurring Psychiatric Disorders. The 
use of pharmacotherapy in people with co-
occurring psychiatric disorders typically involves 
the following considerations:30,31,83,84,85 
	 Naltrexone and acamprosate may be used in 
combination with psychiatric medications. 
There are no known drug interactions
between those classes of medication and 
either drug.
	 If a patient exhibits chronic psychiatric 
symptoms (e.g., depression, mood lability, 
psychosis, anxiety), concurrent pharmacologic 
treatment of the alcohol use disorder and the 
psychiatric comorbidity should be considered.
	 If the patient exhibits symptoms of chronic 
depression or substance-induced depression 
that limits recovery potential, antidepressant 
therapy in the absence of contraindications 
(e.g., a history of mania or hypomania) should 
be considered. 
	 Disulfiram is contraindicated in the presence 
of psychosis because of the risk that it will 
exacerbate psychotic symptoms. 
	 Disulfiram may increase blood levels of 
tricyclic antidepressants and long-acting 
hepatically metabolized benzodiazepines, 
thereby increasing the effects of those 
medications. 
Co-Occurring Medical Conditions and 
Complications. Individuals with alcohol use 
disorder are at high risk for co-occurring medical 
conditions as a result of their heavy drinking and
greater risk of concurrent drug use (which is 
particularly problematic if it involves injection 
drug use), behavioral and social factors such as
unprotected sex and homelessness, or lack of 
regular medical care.85,86,87 Alcohol can also 
interfere with balance and coordination, thus 
predisposing individuals to falls and other 
injuries. Patients who present to emergency 
departments and trauma centers with serious 
injuries are far more likely than members of the 
general population to have engaged in recent 
use of alcohol.88 
Moreover, alcohol affects virtually every organ 
system. Women are more susceptible to many of
the effects of alcohol at lower doses than men 
because of reduced first-pass metabolism of 
alcohol and lower average body weights.89 
MONITORING PATIENT PROGRESS 

As is the case with other chronic relapsing 
disorders, patients diagnosed with an alcohol use 
disorder require long-term monitoring and 
support, as well as periodic adjustment of the 
treatment regimen. 
Monitoring 
Monitoring patient progress is an ongoing 
process, during which the patient is assessed on
three dimensions: (1) adherence to the treatment 
plan; (2) ability to maintain abstinence or reduced
drinking, duration of periods of abstinence or 
reduced drinking, and levels of craving; and (3) 
overall health status and social functioning.1,3,7 
With this information, the clinician can modify the 
treatment plan, decide whether to continue 
pharmacotherapy, and address co-occurring 
medical, psychiatric, and substance use issues.
Sources of Information. Patient self-reports 
can be useful indicators of treatment progress. In
seeking information on treatment progress, it is 
important for the clinician to avoid conveying a 
judgmental attitude toward the patient’s behavior. 
Patients should be asked about the quantity and 
frequency of their drinking, especially during 
stressful periods (e.g., holidays, celebrations, 
major life changes). They should be asked about
current craving and how they felt over the 
preceding week (by assigning a rating between 1 
and 10, with 1 indicating no craving and 10 the 
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most intense craving the patient has ever 
experienced). In addition, patients may be asked 
whether any episodes have caused particular 
problems. Identifying patterns of craving over 
time helps both the patient and the caregiver 
understand that the pattern of craving fluctuates 
throughout the day and even over longer periods, 
indicating the need to continue, adjust, 
supplement, or discontinue use of a particular 
medication. Other information that is useful in 
patient monitoring includes the following:1,2,13 
 	 Instruments such as the eight-question 
Alcohol Urge Questionnaire 
(https://www.phenxtoolkit.org/index.php?page 
Link=browse.protocoldetails&id=520301) 
 Laboratory tests such as the AST, GGT, CDT, 
EtG, and urine drug screens 
 	 The patient’s record of keeping (or not 
keeping) appointments for medication 
monitoring 
 	 The frequency of prescription refills, as 
monitored through the state PDMP90 or direct 
contact with the dispensing pharmacy
 	 Periodic reports from family members (with a 
signed release of information form) 
 	 Periodic status reports from specialty 
substance abuse treatment programs, 
psychiatric referrals, and other psychosocial 
therapy or support 
 	 Any information about other drugs being used
In addition to securing the patient’s PDMP 
record, obtaining information from family 
members and significant others can provide 
useful perspectives on the patient’s behavior and 
level of function, as does contact with or records 
from clinicians who have treated the patient in 
the past and information from the prescription 
benefit provider.91 Ultimately, the goal of 
treatment is to improve the patient’s quality of 
life. Specific areas of patient progress for which 
the patient should be monitored are described in
Table 2.
Adjusting the Treatment Plan  
Alcohol use disorder is a chronic illness that, 
despite treatment, may change in intensity over 
time.2,7,13 If a patient begins to experience 
problems with adherence, the clinician should 
assess the patient for underlying medical, 
psychiatric, or social factors and revisit the 
treatment plan to determine whether different 
strategies or treatment modalities (pharmacologic 
and nonpharmacologic) may be useful. For 
example, increasing the frequency of monitoring 
visits or counseling may enhance the patient’s 
ability to manage relapse risks or stressors that 
are contributing to nonadherence, and switching 
the patient from oral naltrexone to extended-
release injectable naltrexone may enhance 
adherence to the treatment regimen. 
A patient’s goals may change over time, and the 
clinician must adapt to new objectives. Also, as 
with patients who receive treatment for other 
chronic diseases, patients receiving treatment for 
alcohol use disorder may relapse. If this occurs, 
the provider should consider several options:2,24 
 	 Examine social, medical, or behavioral factors 
that contribute to the patient’s alcohol 
consumption 
 Increase monitoring
 Adjust the dose of medication
 Increase or change the intensity of 
psychosocial services 
 Refer the patient for specialty care 
Determining the Duration of Treatment. 
Although the optimal duration of treatment is not 
known, some evidence suggests that treatment 
should continue for at least 6 months to 1 
2,24year.
Because alcohol use disorder is a chronic 
medical problem, patients may need to use 
medications for long periods of time or may 
require multiple episodes of pharmacotherapy. In 
addition, some patients may benefit from 
treatment with medication over short periods to 
help them through particularly stressful situations 
that may elicit cravings for alcohol (e.g., a patient
may ask for disulfiram or naltrexone to use when 
visiting family members who drink excessively).2,7
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TABLE 2: Monitoring Health Status and Social Functioning 
Areas for 
Monitoring Indicators of Progress
Health  Stabilization of medical problems the patient was experiencing before beginningtreatment (e.g., lowered blood pressure; improved liver function; control of blood 
glucose; and stabilization of asthma, cardiomyopathy, encephalopathy, gastritis, ascites, 
edema)
 Signs of increased attention to personal health, such as seeing physicians or other 
health care professionals regularly, increased adherence with prescribed medication 
regimens not related to alcohol treatment (e.g., asthma or blood pressure medications), 
and healthful lifestyle changes
Mental Status§  Reduced irritability and anxiety  Improved mood
 Improved sleep
 Obtaining appropriate treatment for anxiety disorders, suicidal ideation, depression, or 
schizophrenia rather than self-medicating with alcohol
Family/Social 
Activities
 Increases in positive time spent with loved ones 
 Reduced interpersonal conflict 
 Engagement in leisure and recreational activities that do not involve alcohol
Work/School/ 
Vocational 
Status
 Resumption of meaningful activities 
 Gaining employment if previously unemployed
 Engagement in school or other employment preparation
 Stabilized housing 
 Improved work or school performance
Legal Status  Absence of parole or probation violations (in a patient with legal problems)  Absence of new or other legal problems (e.g., driving under the influence charges)
SOURCE: SAMHSA and NIAAA. (2012, September). Report of the SAMHSA-NIAAA Consensus Panel on New and Emerging 
Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities. Rockville, MD: SAMHSA. 
Ideally, a decision to discontinue 
pharmacotherapy will be based on one of the 
following reasons:2,13 
 	 The patient has maintained stable abstinence 
over a sustained period and reports 
substantially diminished craving for alcohol.
 	 The patient feels ready to discontinue the 
medication.
 	 The patient is engaged in ongoing recovery 
activities involving community supports (e.g., 
attendance at mutual-help group meetings).
Some patients simply stop taking their 
medication without consulting the prescriber. Or 
a patient may ask to discontinue medication use 
because of side effects or other reasons. Still 
§ It is recommended that the health care professional administer 
the PHQ-9 screening tool to objectively assess and monitor the 
patient’s mental status over time. http://www.drugabuse.gov 
/sites/default/files/files/PatientHealthQuestionnaire9.pdf
other patients must discontinue medication use 
because of a significant negative laboratory 
finding or a problem with their physical health 
status.2,13 In each situation, the provider should 
help the patient withdraw from the medication at 
an appropriate pace and, as indicated, 
encourage the patient to continue with
psychosocial therapies and participation in 
mutual-help groups.
Referring a Patient for Higher Levels of 
Care. If office-based treatment is not effective or 
the clinician does not have the resources to meet 
a particular patient’s needs, the patient should be
referred for more intensive or specialized 
services.2,7 Many specialty treatment programs 
provide services that address not only immediate 
withdrawal and craving, but also management of 
long-term abstinence through pharmacotherapy; 
case monitoring; individual, group, and 
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family/couples counseling and therapy; other 
psychosocial services including vocational 
counseling; and referral to mutual-help groups.2,24 
A provider who is planning to treat a patient with
an alcohol use disorder should become familiar 
with local treatment resources. Developing 
relationships with treatment staff members 
facilitates consultation and referral. In addition, 
understanding something about a program’s 
treatment duration, modality, philosophy, and 
continuing-care options helps the provider match 
a particular patient to an appropriate treatment 
program.13 It also helps the provider prepare the 
patient for what to expect, thus enhancing 
adherence with a referral.2 
Providers can find programs in their areas or 
throughout the United States by using the 
Behavioral Health Treatment Services  
Locator on the SAMHSA Web site at 
http://www.findtreatment.samhsa.gov. 
SUMMARY 

Medication-assisted treatment has shown much 
promise in reducing alcohol use and promoting 
abstinence in patients diagnosed with alcohol 
use disorder. Considerable research evidence 
and consensus among experts support the use of 
pharmacologic treatments in primary care 
settings.
A number of FDA-approved medications have 
been shown to be important elements of such 
treatment. Although some patients do not benefit
from medication-assisted treatment, most do. For 
each patient deemed an appropriate candidate 
for medication-assisted treatment, multiple 
pharmacologic agents offer a variety of options 
so that treatment can be tailored to each patient’s 
needs and circumstances. 
As new patient care models are encouraged by 
the Patient Protection and Affordable Care Act 
(ACA) and the accompanying improvements in 
the quality and quantity of treatment options that
are anticipated as the ACA is implemented, there 
is considerable potential for expanding the use of
medication-assisted treatment as clinicians
recognize their safety, efficacy, and cost-
effectiveness. 
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APPENDIX B: SOURCES OF HELPFUL 
INFORMATION 
SAMHSA PUBLICATIONS AND WEB 
SITES 
Detoxification and Substance Abuse Treatment, 
Treatment Improvement Protocol 45 
http://www.store.samhsa.gov/product/TIP-45-
Detoxification-and-Substance-Abuse-
Treatment/SMA13-4131 
General Principles for the Use of 
Pharmacological Agents to Treat Individuals with 
Co-Occurring Mental and Substance Use 
Disorders 
http://www.ncdsv.org/images/SAMHSA_General
PrinciplesUsePharmacologicalAgentsTreatIndivid
ualsCo-OccuringMentalSubstanceUseDisorders_ 
2012.pdf   
Incorporating Alcohol Pharmacotherapies Into 
Medical Practice, Treatment Improvement 
Protocol 49 
http://www.store.samhsa.gov/product/TIP-49-
Incorporating-Alcohol-Pharmacotherapies-Into-
Medical-Practice/SMA13-4380   
Naltrexone for Extended-Release Injectable 
Suspension for Treatment of Alcohol 
Dependence, Substance Abuse Treatment 
Advisory 
http://www.store.samhsa.gov/product/Naltrexone-
for-Extended-Release-Injectable-Suspension-for-
Treatment-of-Alcohol-Dependence/SMA07-4267 
Opioid Overdose Toolkit  
http://www.store.samhsa.gov/shin/content/SMA1
3-4742/Overdose_Toolkit_2014_Jan.pdf 
The Role of Biomarkers in the Treatment of 
Alcohol Use Disorders, SAMHSA Advisory 
http://www.store.samhsa.gov/product/The-Role-
of-Biomarkers-in-the-Treatment-of-Alcohol-Use-
Disorders-2012-Revision/SMA12-4686  
SAMHSA’s National Registry of Evidence-based 
Programs and Practices  
http://nrepp.samhsa.gov  
SAMHSA's Screening, Brief Intervention, and 
Referral to Treatment (SBIRT) 
http://www.samhsa.gov/sbirt 
SAMHSA’s Treatment Locator 
http://www.samhsa.gov/treatment  
NIAAA PUBLICATIONS AND WEB SITES  
Alcohol Screening and Brief Intervention for 
Youth: A Practitioner’s Guide 
http://www.niaaa.nih.gov/publications/clinical-
guides-and-manuals/alcohol-screening-and-brief-
intervention-youth/resources  
Assessing Alcohol Problems: A Guide for 
Clinicians and Researchers, Second Edition 
http://www.pubs.niaaa.nih.gov/publications/Asses
singAlcohol 
Clinical Protocols to Reduce High Risk Drinking 
in College Students: The College Drinking 
Prevention Curriculum for Health Care Providers 
http://www.collegedrinkingprevention.gov/media/
FlemingManual.pdf   
Exploring Treatment Options for Alcohol Use 
Disorders, Alcohol Alert, No. 81 
http://www.pubs.niaaa.nih.gov/publications/AA81/
AA81.htm 
Helping Patients Who Drink Too Much: A 
Clinician’s Guide, Updated 2005 Edition 
http://www.pubs.niaaa.nih.gov/publications/Practi
tioner/CliniciansGuide2005/clinicians_guide.htm  
Prescribing Medications for Alcohol Dependence 
http://www.pubs.niaaa.nih.gov/publications/Practi
tioner/CliniciansGuide2005/PrescribingMeds.pdf   
Rethinking Drinking: Alcohol and Your Health 
(available in English and Spanish) 
http://www.pubs.niaaa.nih.gov/publications/Rethi
nkingDrinking/OrderPage.htm 
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MENTORING NETWORK 
Providers’ Clinical Support System for Medication 
Assisted Treatment 
http://www.pcssmat.org
MUTUAL-HELP GROUPS 
Al-Anon Family Groups
http://www.al-anon.alateen.org
Alcoholics Anonymous
http://www.aa.org
Self-Management and Recovery Training
http://www.smartrecovery.org
Women for Sobriety, Inc. 
http://www.womenforsobriety.org
WEB-BASED COURSES 
ASAM e-Live Learning Center  
http://www.softconference.com/asam/default.asp
ASAM From Assessment to Service Planning 
and Level of Care Course 
https://www.changecompanies.net/products/prod 
uct.php?id=ASE2
ASAM Multidimensional Assessment eLearning 
http://www.changecompanies.net/asamcriteria 
/elearning.php
ASAM SBIRT Core Training Program 
http://www.sbirttraining.com 
NIAAA Clinician’s Guide Online Training 
http://www.niaaa.nih.gov/publications/clinical­
guides-and-manuals/niaaa-clinicians-guide­
online-training
NIAAA Presentations and Videocasts
http://www.niaaa.nih.gov/publications/presentatio 
ns-and-videocasts
OTHER WEB SITES 
American Society of Addiction Medicine
http://www.asam.org
Georgetown University Medical Center’s 
Ensuring Solutions to Alcohol Problems 
http://www.ensuringsolutions.org
Gold MS, Aronson, MD. Psychosocial treatment 
of alcohol use disorder. Up-to-date online 
medical education service, 2013. 
http://www.uptodate.com/contents/psychosocial­
treatment-of-alcohol-use-disorder
National Association of State Controlled 
Substances Authorities 
http://www.nascsa.org
U.S. Department of Justice, Drug Enforcement 
Administration, Office of Diversion Control, State 
Prescription Drug Monitoring Programs 
http://www.deadiversion.usdoj.gov/faq/rx_monitor 
.htm
SUGGESTED INSTRUMENTS FOR 
SCREENING AND MONITORING  
Alcohol Misuse: Screening and Behavioral 
Counseling Interventions in Primary Care 
http://www.uspreventiveservicestaskforce.org/us 
pstf/uspsdrin.htm
Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST) 
http://www.who.int/substance_abuse/activities/as 
sist/en/index.html
Alcohol Urge Questionnaire (AUQ) 
https://www.phenxtoolkit.org/index.php?pageLink 
=browse.protocoldetails&id=520301
Alcohol Use Disorders Identification Test 
(AUDIT) 
http://www.whqlibdoc.who.int/hq/2001/WHO_MS 
D_MSB_01.6a.pdf
Clinical Institute Withdrawal Assessment for 
Alcohol Scale, Revised (CIWA-Ar) 
https://umem.org/files/uploads/1104212257_CIW 
A-Ar.pdf
Oregon SBIRT Comprehensive Screening and 
Brief Intervention Resources 
http://www.sbirtoregon.org
Problem Oriented Screening Instrument for 
Teenagers (POSIT) 
http://www.emcdda.europa.eu/html.cfm/index443 
9EN.html
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PUBLISHED GUIDELINES AND 
REFERENCE TEXTS 
American Psychiatric Association (APA). 
Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5). Washington, 
DC: American Psychiatric Publishing, 2013. 
American Psychological Association (APA). 
Understanding Alcohol Use Disorders and Their
Treatment. APA Help Center, 2012.
http://www.apa.org/helpcenter/alcohol­
disorders.aspx
American Society of Addiction Medicine (ASAM). 
ASAM Patient Placement Criteria, Third Edition 
(PPC-3). Philadelphia, PA: Lippincott, Williams & 
Wilkins, 2013. 
American Society of Addiction Medicine (ASAM). 
ASAM Patient Placement Criteria: Supplement 
on Pharmacotherapies for Alcohol Use 
Disorders. Philadelphia, PA: Lippincott, Williams 
& Wilkins, 2010. 
American Society of Addiction Medicine (ASAM). 
ASAM Principles of Addiction Medicine, Fifth 
Edition. Philadelphia, PA: Lippincott, Williams & 
Wilkins, 2014. 
Lingford-Hughes AR, Welch S, Peters L, et al., 
for the British Association of Psychiatry (BAP). 
BAP updated guidelines: Evidence-based 
guidelines for the pharmacological management 
of substance abuse, harmful use, addiction and 
comorbidity. J Psychopharm. 2012; 26(7):899­
952. 
National Clinical Guideline Centre for Acute and 
Chronic Conditions. Alcohol-Use Disorders. 
Diagnosis and Clinical Management of Alcohol-
Related Physical Complications. London, UK: 
National Institute for Health and Clinical 
Excellence, 2010. 
National Clinical Guideline Centre for Acute and 
Chronic Conditions. Alcohol-Use Disorders. 
Diagnosis, Assessment and Management of 
Harmful Drinking and Alcohol Dependence. 
London, UK: National Institute for Health and 
Clinical Excellence, 2011. 
Veterans Health Administration and Department 
of Defense (DoD). VA/DoD Clinical Practice 
Guideline for the Management of Substance Use
Disorders in the Primary Care Setting. 
http://www.healthquality.va.gov/sud/sud_fulltext 
.pdf
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